Logo image of INDP

INDAPTUS THERAPEUTICS INC (INDP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INDP - US45339J2042 - Common Stock

3.15 USD
+0.02 (+0.64%)
Last: 1/12/2026, 8:00:02 PM
3.0612 USD
-0.09 (-2.82%)
After Hours: 1/12/2026, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to INDP. INDP was compared to 528 industry peers in the Biotechnology industry. INDP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INDP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INDP has reported negative net income.
In the past year INDP has reported a negative cash flow from operations.
INDP had negative earnings in each of the past 5 years.
INDP had a negative operating cash flow in each of the past 5 years.
INDP Yearly Net Income VS EBIT VS OCF VS FCFINDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

INDP has a worse Return On Assets (-246.60%) than 89.96% of its industry peers.
With a Return On Equity value of -366.23%, INDP is not doing good in the industry: 73.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -246.6%
ROE -366.23%
ROIC N/A
ROA(3y)-119.69%
ROA(5y)-89.14%
ROE(3y)-188.88%
ROE(5y)-137.07%
ROIC(3y)N/A
ROIC(5y)N/A
INDP Yearly ROA, ROE, ROICINDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INDP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INDP Yearly Profit, Operating, Gross MarginsINDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, INDP has more shares outstanding
INDP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INDP Yearly Shares OutstandingINDP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
INDP Yearly Total Debt VS Total AssetsINDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -20.42, we must say that INDP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.42, INDP is doing worse than 82.39% of the companies in the same industry.
There is no outstanding debt for INDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.42
ROIC/WACCN/A
WACCN/A
INDP Yearly LT Debt VS Equity VS FCFINDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 2.88 indicates that INDP has no problem at all paying its short term obligations.
The Current ratio of INDP (2.88) is worse than 65.15% of its industry peers.
A Quick Ratio of 2.88 indicates that INDP has no problem at all paying its short term obligations.
INDP's Quick ratio of 2.88 is on the low side compared to the rest of the industry. INDP is outperformed by 63.26% of its industry peers.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
INDP Yearly Current Assets VS Current LiabilitesINDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

INDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.24%, which is quite impressive.
EPS 1Y (TTM)34.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

INDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.21% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.79%
EPS Next 2Y36.21%
EPS Next 3Y23.84%
EPS Next 5Y17.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INDP Yearly Revenue VS EstimatesINDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2028 2029 2030 2031 2032 100M 200M 300M 400M
INDP Yearly EPS VS EstimatesINDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

INDP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INDP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INDP Price Earnings VS Forward Price EarningsINDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INDP Per share dataINDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as INDP's earnings are expected to grow with 23.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.21%
EPS Next 3Y23.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INDP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INDAPTUS THERAPEUTICS INC

NASDAQ:INDP (1/12/2026, 8:00:02 PM)

After market: 3.0612 -0.09 (-2.82%)

3.15

+0.02 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-10 2026-03-10/amc
Inst Owners4.11%
Inst Owner Change0%
Ins Owners27.23%
Ins Owner Change1.15%
Market Cap5.51M
Revenue(TTM)N/A
Net Income(TTM)-16.87M
Analysts82.86
Price Target10.2 (223.81%)
Short Float %1.16%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.75%
Min EPS beat(2)3.55%
Max EPS beat(2)29.94%
EPS beat(4)3
Avg EPS beat(4)-6.37%
Min EPS beat(4)-74.29%
Max EPS beat(4)29.94%
EPS beat(8)7
Avg EPS beat(8)7.24%
EPS beat(12)11
Avg EPS beat(12)11.71%
EPS beat(16)15
Avg EPS beat(16)18.53%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.93%
EPS NY rev (1m)0%
EPS NY rev (3m)4.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-31.67
EYN/A
EPS(NY)-6.56
Fwd EYN/A
FCF(TTM)-8.59
FCFYN/A
OCF(TTM)-8.59
OCFYN/A
SpS0
BVpS2.63
TBVpS2.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -246.6%
ROE -366.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.69%
ROA(5y)-89.14%
ROE(3y)-188.88%
ROE(5y)-137.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -20.42
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.74%
EPS Next Y42.79%
EPS Next 2Y36.21%
EPS Next 3Y23.84%
EPS Next 5Y17.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.51%
OCF growth 3YN/A
OCF growth 5YN/A

INDAPTUS THERAPEUTICS INC / INDP FAQ

Can you provide the ChartMill fundamental rating for INDAPTUS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to INDP.


What is the valuation status for INDP stock?

ChartMill assigns a valuation rating of 1 / 10 to INDAPTUS THERAPEUTICS INC (INDP). This can be considered as Overvalued.


Can you provide the profitability details for INDAPTUS THERAPEUTICS INC?

INDAPTUS THERAPEUTICS INC (INDP) has a profitability rating of 0 / 10.


How financially healthy is INDAPTUS THERAPEUTICS INC?

The financial health rating of INDAPTUS THERAPEUTICS INC (INDP) is 5 / 10.